HOOKIPA Pharma Inc. (HOOK)
Fuera de horario:
HOOKIPA Pharma Inc.
350 Fifth Avenue
72nd Floor Suite 7240
New York, NY 10118
United States
431 890 6360
https://www.hookipapharma.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 151
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Malte Peters M.D. | CEO & Director | 191.43k | N/D | 1962 |
| Ms. Mary Theresa Coelho M.B.A. | Executive VP, CFO & Director | 45k | N/D | 1962 |
| Prof. Rolf M. Zinkernagel M.D., Ph.D. | Co-Founder | N/D | N/D | 1944 |
| Mr. Andreas Bergthaler | Co-Founder | N/D | N/D | N/D |
| Mr. Lukas Flatz | Co-Founder | N/D | N/D | N/D |
| Dr. Roman Necina Ph.D. | Chief Operations Officer | N/D | N/D | 1968 |
| Dr. Klaus Orlinger Ph.D. | Chief Scientific Officer | N/D | N/D | 1978 |
| Mr. Matthew L. S. Beck | Executive Director of Investor Relations | N/D | N/D | N/D |
| Mr. Michael Szumera | Executive Director of Communications | N/D | N/D | N/D |
| Dr. Mark Winderlich Ph.D. | Chief Research & Development Officer | N/D | N/D | 1986 |
Descripción
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-200 for the treatment of pembrolizumab which is in Phase 2 of clinical trial; HB-700, a preclinical development for treatment of KRAS mutated cancers, including lung, colorectal, and pancreatic cancers. Its lead product candidates are HB-400 for the treatment of Hepatitis B which is in Phase I of clinical trial and HB-500 for the treatment of HIV which is in Phase I of clinical trial. The company's preclinical stage products include HB-300 program for prostate cancer. It has a collaboration with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus. HOOKIPA Pharma Inc. was incorporated in 2011 and is headquartered in New York, New York.
Gestión corporativa
La calificación ISS Governance QuickScore de HOOKIPA Pharma Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
